Skip to main content
Clinical Trials/ACTRN12605000393651
ACTRN12605000393651Not yet recruitingPhase 1

The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced Cancer as determined by omeprazole metabolism

Cancer Trials New Zealand0 sites50 target enrollmentStarted: September 14, 2005Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to ot stated (—)
Sex
All

Inclusion Criteria

  • Patients with advanced cancer who last received cytotoxic or hormonal therapy for their cancer more than four weeks ago and who are being considered for a new line of therapy for disease progression or inadequate response to prior therapy; adequate renal and liver function; Patients must be able to provide informed consent

Exclusion Criteria

  • Patients receiving medication which is either a CYP2C19 inhibitor or inducer.

Investigators

Sponsor
Cancer Trials New Zealand

Similar Trials